Grants and Contracts Details
ABSTRACT COPIED FROM CLINICALTRIALS.GOV This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of IMGN853 to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.
|Effective start/end date||6/8/17 → 3/14/19|
- Gynecological Oncology Group Foundation Incorporated: $20,548.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.